Navigation Links
Vasogen Announces Sale of Patent Application and Provides Corporate Update
Date:2/2/2009

MISSISSAUGA, ON, Feb. 2 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today announced that it has sold a United States patent application and its related foreign counterparts for US$400,000. This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it relates to its Celacade System.

The Company today also announced that it continues to advance the process associated with its ongoing strategic review and expects to be in a position to provide a further update to shareholders over the coming weeks. As previously announced, Vasogen has been reviewing various strategic alternatives for the purpose of enhancing shareholder value.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to complete a sale, merger, acquisition, or other strategic alternative, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You s
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
2. Vasogen Provides Corporate Update
3. Vasogen Announces Third Quarter 2008 Results
4. Vasogen Announces Second Quarter 2008 Results
5. Vasogen Provides Corporate Update
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
8. Vasogen Announces Implementation of Strategic Restructuring Plan
9. Vasogen Announces First Quarter 2008 Results
10. Vasogen to Webcast its Annual Meeting
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... BEIJING, May 1 Sinovac Biotech Ltd. (NYSE Amex: ... in China, today announced that it has filed its Annual ... Commission for the year ended December 31, 2008 on May ... now available on the Company,s website under the investor relations ...
... of $79.7 Million, Increase of 29% over First Quarter 2008- ... per Diluted Share, Increases of 14% and 20% over First ... Therapeutics Corporation (Nasdaq: UTHR ) today announced its ... Total revenues for the first quarter of 2009 were ...
... Earnings Conference Call to be Held on May 15, ... / 8:00 pm (Beijing/Shanghai/Hong Kong)SHANGHAI, May 1 /PRNewswire-Asia/ -- ... a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... today announced that it will release financial results for ...
Cached Biology Technology:Sinovac Biotech Ltd. Files Annual Report on Form 20-F 2United Therapeutics Reports First Quarter 2009 Financial Results 2United Therapeutics Reports First Quarter 2009 Financial Results 3United Therapeutics Reports First Quarter 2009 Financial Results 4United Therapeutics Reports First Quarter 2009 Financial Results 5United Therapeutics Reports First Quarter 2009 Financial Results 6United Therapeutics Reports First Quarter 2009 Financial Results 7WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... 2008 American Society for Microbiology (ASM) Siemens ... presented to Adrian M. Zelazny, Staff Scientist, ... Institutes of Health (NIH). This award recognizes ... antimicrobial therapy. Dr. Zelazny is honored ...
... of supercomputers have hardware set up not just for ... seemingly random data. And now, a multi-institutional group of ... for these supercomputers. Applications include anywhere complex webs of ... grid stability to complex biological networks. The ...
... from infecting other cells and triggering their destruction by ... HIV-infected individuals but eventually peters out. To find out ... Infectious Diseases examined the cells that make the antibodies, ... that HIV gradually depletes the numbers of healthy, functional ...
Cached Biology News:Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3
...
...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Request Info...
Biology Products: